Biosimilar Competition Market 2019 |Is Heating-up! Have You Mapped Your Competitors?

Biosimilar approvals have increased steeply in the recent years. Europe leads in terms of biosimilar approvals. However, the U.S. has also shown significant growth in terms of biosimilar approvals. Sandoz’s Zarxio, a biosimilar to Amgen’s bone marrow stimulant Neupogen (filgrastim) — was the first biosimilar approved in the U.S., followed by three approvals in 2016. The number has increased to nine in 2017 and hit a record number of 16 in 2018. That’s a significant rise of 131% compared to the number of trials in 2016.

Asia is a major region in the global biosimilar phase 3 and above pipeline products list. Companies such as Reliance LifeSciences, Intas Pharmaceuticals, Biocon, and Samsung Bioepis are the leading Asian companies for biosimilars.

This intense competition has led to fierce price discounts. Biosimilars of Humira, for instance, in Nordic countries, are available at 10%-80% discounted rate of the biological brand. Biosimilars of Humira, in Norway, are available at a discounted price of 80%. This is mainly because of the tender system operating in the country. However, Abbvie, the company marketing Humira, expects double digit growth in 2019. Besides, its major market – U.S., is secured till 2023, as the approved biosimilars will not enter until then under the agreed terms with Abbvie, except for Boehringer Ingelheim’s Cyltezo, with whom the litigation is still on-going.

Enquire about Phase-XS Now: https://www.coherentmarketinsights.com/phase-xs/request-a-call-back

On the other hand, sales of Neupogen fell 40% in the fourth quarter of 2018, owing to intense biosimilar competition. Amgen, who is marketing Neupogen, on account of biosimilar competition, has posted a conservative guidance for 2019.

Moreover, PHASE-XS database shows that there are nine biosimilar trials in non-oncology category. Dermatology and rheumatology are the leading non-oncology target therapeutic categories for biosimilars in the U.S. PHASE-XS, which is a comprehensive database of biologics and biosimilar pipeline products, highlights the market potential for pipeline products, reimbursement, expected product price, expected approval and launch year, addressable patient pool, adherence rate (for the U.S. Market) and drug switch (for the U.S. Market).

PHASE-XS is a biosimilar pipeline database as well as biosimilar pipeline database. This is a proprietary database developed by Coherent Market Insights, which is a market intelligence and consulting firm.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

About Us:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

This release was published on openPR.